Category: Regulations

Clues to How Macron Achieves Major Free Market Reforms in France

(p. A9) PARIS — The plush red velvet seats of France’s National Assembly are filled with lawmakers who owe just about everything to President Emmanuel Macron.
Three-quarters of the 577 members are brand new, swept into power in the wake of his election last year. More than 60 percent are in his camp. Nearly one-third have never held public office, and 38 were under the age of 31 when they entered office.
. . .
On Thursday [March 22, 2018], tens of thousands of railway workers, teachers and air traffic controllers went on strike across France to protest salary freezes for civil servants and Mr. Macron’s pledge to cut 120,000 public-sector jobs and introduce merit-based pay and use more private contractors.
. . .
The assembly has become a showcase of Mr. Macron’s forceful powers of persuasion and the ways he wants to reshape and update all of France.
“There’s been a complete cultural shock,” said Jean-Paul Delevoye, a senior official in Mr. Macron’s government who helped pick his candidates for Parliament.
“We’ve completely overturned the sociology of the assembly,” he added.
Diet Coke replaced wine as the most popular item at the assembly’s bar. Wine sales had plummeted, stunning the barmen, though they are creeping back up under the influence of long days. Mr. Macron’s acolytes sit through them, unlike their predecessors.
Before the rule for a deputy was, arrive Tuesday morning and go home Wednesday evening. Now, many say, Mr. Macron’s deputies come for the whole week.
So assiduous are they that “now, it’s hard to find a spot at the restaurant, that’s what strikes me,” said Brigitte Bourguignon, another ex-Socialist who joined Mr. Macron.
Among the youthful deputies, common positions are worked out in advance on applications like Telegram, befuddling the old-timers. There is little patience for them in any case.
. . .
Parliament was barely to be seen last year when Mr. Macron forced through changes to France’s rigid labor code to allow companies more flexibility in negotiating directly with workers, and to limit payouts after layoffs.
Instead, the president proceeded by special decree, using a rarely used procedure that allowed the National Assembly merely to vote thumbs up or down on the labor reforms — it voted up — but without the power to change or even discuss them.
Then, Mr. Macron rammed through the lifting of a tax on wealth, insisting that it was necessary to free capital for investment. Many economists agreed. But apart from a few opposition whimpers there was hardly any debate.
In coming weeks he proposes to take on the railway workers — the bête noir of many a French government — again by special decree. Mr. Macron wants to end the hiring-for-life, early retirement and enhanced medical insurance that have contributed to a whopping deficit. But he doesn’t necessarily want Parliament debating it.
. . .
For his dedicated supporters in Parliament, subordination is not an issue. Asked whether he had been in disagreement with the government, Mr. Potterie replied: “Ah, no. No. At the margins maybe. But for the moment, no.”
In the National Assembly, “it’s true that we don’t challenge the government,” he added. “It’s because we were elected to carry out their program.”
That sense of purpose runs deep.
“It’s not true that we are simply puppets,” insisted Ms. Bourguignon, the former Socialist. “We’ve got a government that reforms, and we’ve got to follow the government.”

For the full story, see:
ADAM NOSSITER. “Macron Fills the Role Of French Strongman.” The New York Times (Friday, March 23, 2018): A9.
(Note: ellipses, and bracketed date, added.)
(Note: the online version of the story has the date MARCH 22, 2018, and has the title “Emmanuel Macron Becomes France’s Answer to Strongman Populism.” The online version says that the article appeared on p. A13 of the New York edition. It appeared on p. A9 of my National edition.)

Big Pharma Is Mellow about FDA Obstacles to Innovation

It sometimes appears that big pharma is comfortable with the hugely expensive FDA drug approval process. Perhaps big pharma firms have learned how to navigate the process and have the resources to do so. And perhaps the process discourages disruptive innovations from small medical startups that have not learned how to navigate the process, and do not have the resources to do so. If so, then the puzzling indifference of big pharma indicated in the passages quoted below, becomes easier to understand.
(There’s a wonderful recent TV ad from big pharma supporting innovation by quoting the Dylan Thomas poem saying we should “rage, rage against the dying of the light.” If only they really meant it.)

(p. A13) In recent years, the arrival of breakthrough drugs for everything from cancer to rare diseases has led to a surge in the number of patients wanting early access to treatments. The pleas — sometimes driven by viral social media campaigns — have proved vexing for companies that have invested millions to get a drug to market and are wary of doing anything to jeopardize their chances.

Today, companies’ policies on granting early access to drugs are a confusing patchwork that tends to favor affluent and well-connected patients at leading medical centers, who have the resources and know-how to navigate the system.
“You have to be pretty sophisticated,” said Dr. Arthur L. Caplan, a bioethicist at New York University who has been working with companies, including Johnson & Johnson, to develop better early-access programs. But the bill passed this week, he said, “does somewhere between nothing and absolutely nothing to help you.”
The bill’s passage represented a victory for proponents of “right to try,” a campaign championed by Vice President Mike Pence and initiated by the Goldwater Institute, a libertarian think tank that favors limiting the scope of the F.D.A. At least 38 states have passed local versions of right-to-try laws, which allow patients to sidestep F.D.A. approval once they have received permission from a company.
The right-to-try measures are opposed by a broad coalition of groups, which contend the bill will not help patients and will undermine the authority of the primary regulatory agency, the F.D.A. Four former F.D.A. commissioners, including two each from Democratic and Republican administrations, oppose the bills, as do dozens of patient groups, including the American Cancer Society Cancer Action Network and the American Lung Association.
The pharmaceutical industry, while not taking a position on the issue, has been circumspect. A spokesman for its main lobbying group, the Pharmaceutical Research and Manufacturers of America, said on Friday, “We believe any legislation must truly benefit and protect patients and not disrupt the future of clinical trials, U.S. Food and Drug Administration oversight and the research and approval of new medicines.”
. . .
The F.D.A. already approves 99 percent of such applications, and the agency has streamlined the approval process. Drug companies also have many other reasons to bar access — often, companies do not have enough extra product to give to patients, or they worry that the logistical work of granting access could slow efforts to get the drug approved, when it would become available to any patient who needed it.
There is also the possibility that the drug does not work — many experimental products fail in late-stage trials.
. . .
“In our view, the F.D.A. plays a really important role,” Dr. Joanne Waldstreicher, the chief medical officer of Johnson & Johnson, said in an interview Thursday. Johnson & Johnson initiated a program in 2015 that delegates decisions about early access to a program set up by Dr. Caplan. The F.D.A., Dr. Waldstreicher said, has “information that we don’t have necessarily; they see safety and efficacy information on products that may be similar.”

For the full story, see:
KATIE THOMAS. “For Terminally Ill People, a Convoluted Procedure Just to Give Drugs a Try.” The New York Times (Saturday, March 24, 2018): A13.
(Note: ellipses added.)
(Note: the online version of the story has the date March 23, 2018, and has the title “Why Can’t Dying Patients Get the Drugs They Want?”)

“A Litigious, Protective Culture Has Gone Too Far”

(p. A1) SHOEBURYNESS, England — Educators in Britain, after decades spent in a collective effort to minimize risk, are now, cautiously, getting into the business of providing it.
. . .
Limited risks are increasingly cast by experts as an experience essential to childhood development, useful in building resilience and grit.
Outside the Princess Diana Playground in Kensington Gardens in London, which attracts more than a million visitors a year, a placard informs parents that risks have been “intentionally provided, so that your child can develop an appreciation of risk in a controlled play environment rather than taking similar risks in an uncontrolled and unregulated wider world.”
This view is tinged with nostalgia for an earlier Britain, in which children were tougher and more self-reliant. It resonates both with right-wing tabloids, which see it as a corrective to the cosseting of a liberal nanny state; and with progressives, drawn to a freer and more natural childhood.
. . .
(p. A12) Britain is one of a number of countries where educators and regulators say a litigious, protective culture has gone too far, leaching healthy risks out of childhood. Guidelines on play from the government agency that oversees health and safety issues in Britain state that “the goal is not to eliminate risk.”

For the full story, see:
ELLEN BARRY. “In Britain, Learning to Accept Risk, and the Occasional ‘Owie’.” The New York Times, First Section (Sunday, March 11, 2018): A1 & A12.
(Note: ellipses added.)
(Note: the online version of the story has the date MARCH 10, 2018, and has the title “In Britain’s Playgrounds, ‘Bringing in Risk’ to Build Resilience.”)

Silicon Valley Warms to Trumps Lower Taxes and Deregulation

(p. B1) SAN FRANCISCO — Two days after Donald J. Trump won the 2016 election, executives at Google consoled their employees in an all-staff meeting broadcast around the world.
“There is a lot of fear within Google,” said Sundar Pichai, the company’s chief executive, according to a video of the meeting viewed by The New York Times. When asked by an employee if there was any silver lining to Mr. Trump’s election, the Google co-founder Sergey Brin said, “Boy, that’s a really tough one right now.” Ruth Porat, the finance chief, said Mr. Trump’s victory felt “like a ton of bricks dropped on my chest.” Then she instructed members of the audience to hug the person next to them.
Sixteen months later, Google’s parent company, Alphabet, has most likely saved billions of dollars in taxes on its overseas cash under a new tax law signed by Mr. Trump. Alphabet also stands to benefit from the Trump administration’s looser regulations for self-driving cars and delivery drones, as well as from proposed changes to the trade pact with Mexico and Canada that would limit Google’s liability for user content on its sites.
Once one of Mr. Trump’s most vocal opponents, Silicon Valley’s technology industry has increasingly found common ground with the White House. When Mr. Trump was elected, tech executives were largely up in arms over a leader who espoused policies on immigration and other issues that were antithetical to their companies’ values. Now, many of the industry’s executives are growing more comfortable with the president and how his (p. B5) economic agenda furthers their business interests, even as many of their employees continue to disagree with Mr. Trump on social issues.
. . .
. . . quietly, the tech industry has warmed to the White House, especially as companies including Alphabet, Apple and Intel have benefited from the Trump administration’s policies.
Those include lowering corporate taxes, encouraging development of new wireless technology like 5G and, so far, ignoring calls to break up the tech giants. Mr. Trump’s tougher stance on China may also help ward off industry rivals, with the president squashing a hostile bid to acquire the chip maker Qualcomm this month. And Mr. Trump let die an Obama-era rule that required many tech start-ups to give some workers more overtime pay.
Mr. Trump “has been great for business and really, really good for tech,” said Gary Shapiro, who leads the Consumer Technology Association, the largest American tech trade group, with more than 2,200 members including Apple, Google, Amazon and Facebook.
Mr. Shapiro said that he had voted for Hillary Clinton, Mr. Trump’s opponent, in 2016, but that he and many tech executives had come around on Mr. Trump. While they disagree with him on immigration and the environment, they have found areas where their interests align, like deregulation and investment in internet infrastructure.
“This isn’t Hitler or Mussolini here,” Mr. Shapiro said. And even though the president’s new tariffs on steel and aluminum could hurt American businesses and consumers, “disagreement in one area does not mean we cannot work together in others,” Mr. Shapiro said. “Everyone who is married knows that.”

For the full story, see:

JACK NICAS. “Silicon Valley, Wary of Trump, Warms to Him.” The New York Times (Saturday, March 31, 2018): B1 & B5.
(Note: ellipses added.)
(Note: the online version of the story has the date MARCH 30, 2018, and has the title “Silicon Valley Warms to Trump After a Chilly Start.”)

“Science Didn’t Lie”

(p. 22) In the words of The Saturday Evening Post: “If America doesn’t keep out the queer, alien, mongrelized people of Southern and Eastern Europe, her crop of citizens will eventually be dwarfed and mongrelized in turn.”
According to Thomas C. Leonard, who teaches at Princeton, the driving force behind this and other such laws came from progressives in the halls of academia — people who combined “extravagant faith in science and the state with an outsized confidence in their own expertise.” “Illiberal Reformers” is the perfect title for this slim but vital account of the perils of intellectual arrogance in dealing with explosive social issues. Put simply, Leonard says, elite progressives gave respectable cover to the worst prejudices of the era — not to rabble-rouse, but because they believed them to be true. Science didn’t lie.
But barring undesirables was only half the battle; the herd also had to be culled from within. In 1907, Indiana became the first state to legalize forced sterilization, starting a landslide endorsed by progressive icons like Theodore Roosevelt and the birth control champion Margaret Sanger.

For the full review, see:
DAVID OSHINSKY. “No Justice for the Weak.” The New York Times Book Review (Sunday, March 20, 2018): 1 & 22-23.
(Note: the online version of the review has the date March 14, 2018, and has the title “‘Imbeciles’ and ‘Illiberal Reformers’.”)

The book under review, is:
Leonard, Thomas C. Illiberal Reformers: Race, Eugenics, and American Economics in the Progressive Era. Princeton, NJ: Princeton University Press, 2016.

Dockless Scooter Startups Follow Uber in Asking Regulators for Forgiveness Instead of Permission

(p. B1) Electric scooters have arrived en masse in cities like Los Angeles, San Francisco and Washington, with companies competing to offer the dockless and rechargeable vehicles. Leading the pack is Mr. VanderZanden’s Bird, with rivals including Spin and LimeBike. The start-ups are buoyed with more than $250 million in venture capital and a firm belief that electric scooters are the future of transportation, at least for a few speedy blocks.
The premise of the start-ups is simple: People can rent the electric scooters for about a $1, plus 10 cents to 15 cents a minute to use, for so-called last-mile transportation. To recharge the scooters, (p. B5) the companies have “chargers,” or people who roam the streets looking to plug in the scooters at night, for which they get paid $5 to $20 per scooter.
The problem is that cities have been shocked to discover that thousands of electric scooters have been dropped onto their sidewalks seemingly overnight. Often, the companies ignored all the usual avenues of getting city approval to set up shop. And since the scooters are dockless, riders can just grab one, go a few blocks and leave it wherever they want, causing a commotion on sidewalks and scenes of scooters strewn across wheelchair ramps and in doorways.
So officials in cities like San Francisco and Santa Monica, Calif., have been sending cease-and-desist notices and holding emergency meetings. Some even filed charges against the scooter companies.
“They just appeared,” said Mohammed Nuru, director of the San Francisco Public Works, which has been confiscating the scooters. “I don’t know who comes up with these ideas or where these people come from.”
Dennis Herrera, the San Francisco city attorney who sent cease-and-desist letters to Bird and others, described the chaos as “a free for all.”
Mr. VanderZanden said given how enormous a social shift he believes his scooters are, he was not surprised it ruffled some feathers. But people would eventually adjust, he said.
“Go back to the early 1900s, and people would have a similar reaction to cars because they were used to horses,” he said. “They had to figure out where to park all the dockless cars.”
If there is something familiar about these scooter companies’ strategy of just showing up in cities without permission, that’s because that has now become a tried-and-true playbook for many start-ups. In its early days, Uber, the ride-hailing giant, also barreled into towns overnight to launch its service and only asked for forgiveness later.
“Cities don’t know what it is,” Caen Contee, the head of marketing for LimeBike, said of the arrival of electric scooters. “They don’t know how to permit it until they’ve seen it.”
. . .
“My brother and sister legislators from Santa Monica warned me that that phenomenon has hit their cities,” said Aaron Peskin, who is on San Francisco’s board of supervisors, the city’s legislative branch. Referring to the scooter start-ups, he added, “These people are out of their minds.”

For the full story, see:
Nellie Bowles and David Streitfeld. “Charged Up Over Scooters Despite Uproar.” The New York Times (Sat., April 21, 2018): B1 & B5.
(Note: ellipsis added.)
(Note: the online version of the story has the date April 20, 2018, and has the title “Electric Scooters Are Causing Havoc. This Man Is Shrugging It Off.”)

The Role of Progressives in the Forced Sterilization of Thousands

(p. 22) Progressivism was always more than a single cause, however. Attracting reformers of all stripes, it aimed to fix the ills of society through increased government action — the “administrative state.” Progressives pushed measures ranging from immigration restriction to eugenics in a grotesque attempt to protect the nation’s gene pool by keeping the “lesser classes” from reproducing. If one part of progressivism emphasized fairness and compassion, the other reeked of bigotry and coercion.
“Imbeciles,” by Adam Cohen, the author of “Nothing to Fear: FDR’s Inner Circle and the Hundred Days That Created Modern America,” examines one of the darkest chapters of progressive reform: the case of Buck v. Bell. It’s the story of an assault upon thousands of defenseless people seen through the lens of a young woman, Carrie Buck, locked away in a Virginia state asylum. In meticulously tracing her ordeal, Cohen provides a superb history of eugenics in America, from its beginnings as an offshoot of social Darwinism — ­human survival of the fittest — to its rise as a popular movement, advocating the state-sponsored sterilization of “feeble­minded, insane, epileptic, inebriate, criminalistic and other degenerate persons.”

For the full review, see:
DAVID OSHINSKY. “No Justice for the Weak.” The New York Times Book Review (Sunday, March 20, 2018): 1 & 22-23.
(Note: the online version of the review has the date March 14, 2018, and has the title “‘Imbeciles’ and ‘Illiberal Reformers’.”)

The book under review, is:
Cohen, Adam. Imbeciles: The Supreme Court, American Eugenics, and the Sterilization of Carrie Buck. New York: Penguin Press, 2016.

Dockless Bikes Flood Dallas as Officials Scramble to Regulate

(p. B4) . . . in recent months, Dallas has become ground zero for a nascent national bike-share war, as five startups armed with hundreds of millions of venture capital dollars have blanketed the city with at least 18,000 bikes.   . . .    . . . , the bikes flooding Dallas are “dockless.” In other words, these bikes–popular in many Chinese cities–can be left almost anywhere when the rider is done.
. . .
City officials are scrambling to write regulations. “You drive down a street, you see bikes everywhere, all scattered out,” said Dallas City Council member Tennell Atkins. “We’ve got to think it through. It’s a mess.”
Other U.S. cities are having a similar experience, if on a smaller scale. The startups, which include China’s two leading bike-share companies, are in the early stages of a plan to blanket U.S. cities with hundreds of thousands of dockless bikes in the coming year.
Typically acting with cooperation and encouragement from city governments, companies seed a city with bikes placed on sidewalks, by bus stops and throughout downtowns. Users pay $1 per half-hour or hour for a bike they locate and unlock with an app on their smartphones, eliminating the need for a bike rack.

For the full story, see:
Eliot Brown. “It’s the Wild West for Bike Sharing.” The Wall Street Journal (Tuesday, March 27, 2018): B4.
(Note: ellipses added.)
(Note: the online version of the story has the date March 26, 2018, and has the title “Dockless Bike Share Floods into U.S. Cities, With Rides and Clutter.”)

Blockchain Tested to Speed Property Transfers

(p. B8) The blockchain technology that underpins cryptocurrencies such as bitcoin could change the way property deals are done and recorded more than any other new technology, real-estate and technology experts say.
And Sweden’s nearly 400-year-old land mapping and registration authority is likely to become one of the first government agencies to test using blockchain technology for conducting property sales.
The Lantmäteriet expects to conduct the first such transaction in the next few months and is shortlisting volunteers who want to buy or sell a property using the blockchain system. “From the technology point of view, we are quite ready,” said Mats Snäll, Lantmäteriet’s chief digital officer.
Proponents of blockchain say the technology would make recording and transferring titles faster and much more efficient. Transactions that today take months to complete could take days or even hours, they say.
Blockchain technology also is practically bulletproof when it comes to fraudulent transactions, experts say.

For the full story, see:
Shefali Anand. “Test of Blockchain for Real Estate Is Readied.” The Wall Street Journal (Wednesday, March 7, 2018): B8.
(Note: the online version of the story has the date March 6, 2018, and has the title “A Pioneer in Real Estate Blockchain Emerges in Europe.”)

Patients Lower Blood Pressure Best When It Is Self-Monitored

(p. D4) The most effective way to monitor blood pressure may be to do it yourself.
British researchers randomly assigned 1,003 patients with hypertension to one of three groups.
. . .
The study was published in Lancet.
“People who monitor their own blood pressure and share the readings with their physician get better control,” said the lead author, Dr. Richard J. McManus, a professor of primary care at the University of Oxford. “Seventy-five million Americans have hypertension. If a good proportion of those self-monitored, it would lead to a big reduction in stroke.”

For the full story, see:
NICHOLAS BAKALAR. “The Best Way to Monitor Your Blood Pressure? Do It Yourself.” The New York Times (Tuesday, MARCH 13, 2018): D4.
(Note: ellipsis added.)
(Note: the online version of the story has the date MARCH 6 [sic], 2018, and has the title “The Best Way to Monitor Your Blood Pressure? Do It Yourself.”)

The Lancet study summarized above, is:
McManus, Richard J., Jonathan Mant, Marloes Franssen, Alecia Nickless, Claire Schwartz, James Hodgkinson, Peter Bradburn, Andrew Farmer, Sabrina Grant, Sheila M. Greenfield, Carl Heneghan, Susan Jowett, Una Martin, Siobhan Milner, Mark Monahan, Sam Mort, Emma Ogburn, Rafael Perera-Salazar, Syed Ahmar Shah, Ly-Mee Yu, Lionel Tarassenko, F. D. Richard Hobbs, Brendan Bradley, Chris Lovekin, David Judge, Luis Castello, Maureen Dawson, Rebecca Brice, Bethany Dunbabin, Sophie Maslen, Heather Rutter, Mary Norris, Lauren French, Michael Loynd, Pippa Whitbread, Luisa Saldana Ortaga, Irene Noel, Karen Madronal, Julie Timmins, Peter Bradburn, Lucy Hughes, Beth Hinks, Sheila Bailey, Sue Read, Andrea Weston, Somi Spannuth, Sue Maiden, Makiko Chermahini, Ann McDonald, Shelina Rajan, Sue Allen, Brenda Deboys, Kim Fell, Jenny Johnson, Helen Jung, Rachel Lister, Ruth Osborne, Amy Secker, Irene Qasim, Kirsty William, Abi Harris, Susan Zhao, Elaine Butcher, Pauline Darbyshire, Sarah Joshi, Jon Davies, Claire Talbot, Eleanor Hoverd, Linda Field, Tracey Adcock, Julia Rooney, Nina Cooter, Aaron Butler, Naomi Allen, Maria Abdul-Wahab, Kathryn McNicholas, Lara Peniket, Kate Dodd, Julie Mugurza, Richard Baskerville, Rakshan Syed, Clare Bailey, Jill Adams, Paul Uglow, Neil Townsend, Alison Macleod, Charlotte Hawkins, Suparna Behura, Jonathan Crawshaw, Robin Fox, Waleed Doski, Martin Aylward, Christine A’Court, David Rapley, Jo Walsh, Paul Batra, Ana Seoane, Sluti Mukherjee, Jonathan Dixon, Peter Arthur, Karen Sutcliffe, Costas Paschallides, Richard Woof, Peter Winfrey, Matthew Clark, Roya Kamali, Paul Thomas, David Ebbs, Liz Mather, Andre Beattie, Karim Ladha, Larisa Smondulak, Surinder Jemahl, Peter Hickson, Liam Stevens, Tony Crockett, David Shukla, Ian Binnian, Paul Vinson, Nigel DeKare-Silver, Ramila Patel, Ivor Singh, Louise Lumley, Glennis Williams, Mark Webb, Jack Bambrough, Neetul Shah, Hergeven Dosanjh, Frank Spannuth, Carolyn Paul, Jude Ganesegaram, Laurie Pike, Vijaysundari Maheswaran, Farah Paruk, Stephen Ford, Vineeta Verma, Kate Milne, Farhana Lockhat, Jennifer Ferguson, Anne-Marie Quirk, Hugo Wilson, David Copping, Sam Bajallan, Simria Tanvir, Faheem Khan, Tom Alderson, Amar Ali, Richard Young, Umesh Chauhan, Lindsey Crockett, Louise McGovern, Claire Cubitt, Simon Weatherill, Abdul Tabassum, Philip Saunders, Naresh Chauhan, Samantha Johnson, Jo Walsh, Inderjit Marok, Rajiv Sharma, William Lumb, John Tweedale, Ian Smith, Lawrence Miller, Tanveer Ahmed, Mark Sanderson, Claire Jones, Peter Stokell, Matthew J. Edwards, Andrew Askey, Jason Spencer, Kathryn Morgan, Kyle Knox, Robert Baker, Crispin Fisher, Rachel Halstead, Neil Modha, David Buckley, Catherine Stokell, John Gerald McCabe, Jennifer Taylor, Helen Nutbeam, Richard Smith, Christopher MacGregor, Sam Davies, Mark Lindsey, Simon Cartwright, Jonathan Whittle, Julie Colclough, Alison Crumbie, Nicholas Thomas, Vattakkatt Premchand, Rafia Hamid, Zishan Ali, John Ward, Philip Pinney, Stephen Thurston, and Tina Banerjee. “Efficacy of Self-Monitored Blood Pressure, with or without Telemonitoring, for Titration of Antihypertensive Medication (TASMINH4): An Unmasked Randomised Controlled Trial.” The Lancet 391, no. 10124 (March 10, 2018): 949-59.

Government Obstacles Slow 5G Innovation

(p. A13) . . . , governmental obstacles threaten to block a new wave of wireless innovation, known as fifth generation or “5G.” It will multiply download speeds by at least 10 times, allowing wireless carriers to compete with cable companies for high-speed internet access. With superfast speeds and low lag times, 5G will enable advances in everything from driverless cars to the “tactile internet,” in which surgeons can perform operations and builders operate construction equipment remotely, and entertainment can include sensations beyond the audiovisual.
. . .
In some places, outdated local requirements prohibit carriers from placing small cells in local rights-of-way and on government-owned utility poles. Zoning ordinances designed for much larger towers often require local zoning boards to approve small cells. Some localities refuse altogether to negotiate right-of-way access, while others impose prohibitive fees and other unreasonable conditions.

For the full story, see:
Robert McDowell. “Local Laws Imperil 5G Innovation; Misapplied zoning rules and huge fees block antennas the size of pizza boxes.” The Wall Street Journal (Tuesday, April 3, 2018): A13.
(Note: ellipses added.)
(Note: the online version of the story has the date APRIL 2, 2018.)